AstraZeneca plc 12.8% Potential Upside Indicated by Barclays Capital

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc with EPIC/TICKER (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OVERWEIGHT’ today by analysts at Barclays Capital. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set their target price at 8300 GBX on its stock. This indicates the analyst now believes there is a potential upside of 12.8% from today’s opening price of 7355 GBX. Over the last 30 and 90 trading days the company share price has increased 436 points and increased 100 points respectively. The 52 week high for the stock is 7646 GBX while the 52 week low is 5312 GBX.

AstraZeneca plc has a 50 day moving average of 7,256.45 GBX and a 200 Day Moving Average share price is recorded at 6,672.72. There are currently 1,311,904,600 shares in issue with the average daily volume traded being 1,920,740. Market capitalisation for LON:AZN is £98,117,345,034 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
    AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

      Search

      Search